Abeona Therapeutics (ABEO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Abeona Therapeutics

NasdaqCM•Healthcare•Biotechnology

$5.43+0.06(0.01%)Market open

Market Cap

$306.35M

P/S

12.0x

P/B

2.4x

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

How this company scores

AverageMetricSide Score: 50/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Profitability (7/25).

Profitability7/25

Growth14/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality8/25

Strengths

Growing revenueLow leverageCash-backed earningsImproving leverage

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 3.6x5y range 3.5x – 5.2x

Currently near its 4-quarter median.

P/S · 12.0x5y range 4.4x – 745.8x

Currently below its 16-quarter median.

P/B · 2.4x5y range 0.7x – 7.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $306.35M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $25.52M
Q. Revenue: $11.38M
TTM EBITDA: $-80.81M
TTM Op. Income: $-83.61M
Q. Op. Income: $-13.65M
TTM Net Income: $-62.89M
Q. Net Income: $-20.19M
EPS: $-0.35
Shares Out.: $57.05M

$25.52M in TTM revenue grew 6280.0% YoY, reaching $11.38M last quarter. TTM EBITDA of $-80.81M and TTM operating income of $-83.61M show growth is flowing through to the bottom line. However, net income is negative at $62.89M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 3 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 63.3%
EBITDA Margin: -113.8%
Op. Margin: -120.0%
Net Margin: -177.4%

Op. margin of -120.0% is up 5578.0% YoY — cost efficiency is improving. Net margin at -177.4% and gross margin of 63.3% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 12.0x
P/B Ratio: 2.4x

P/S of 12.0x and P/B of 2.4x. P/S is high, meaning growth expectations are priced in. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $179.51M
Cash: $56.23M
Long-Term Debt: $1.66M
Book Value: $128.06M
D/E Ratio: 0.0
Debt/EBITDA: N/A

With $179.51M in assets and $1.66M in long-term debt, D/E is 0.0and book value is $128.06M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-17.50M
TTM Free Cash Flow: $-81.53M
FCF Margin: -319.5%
FCF / Net Income: 1.3

TTM FCF of $-81.53M on $-17.50M in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 14% — an improving trend.